Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study
Authors:
Open Access
- 27 May 2026
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8030-8040
Abstract
Background: Immune checkpoint inhibitors (ICIs) have become a viable treatment method for unresectable or recurrent esophageal squamous cell carcinoma (ESCC). However, the relationships between early tumor shrinkage (ETS) and clinical outcomes for ESCC patients receiving ICIs remain unknown. This observational study investigated the associations between ETS and clinical outcomes for patients with unresectable or recurrent ESCC who received ICIs. Methods: Early tumor shrinkage was defined as the percentage decreases at the first evaluation, and the ETS cutoff value was 20%. Using an unbiased database of 128 unresectable or recurrent ESCC patients who received ICI plus chemotherapy or ICI plus ICI, this study evaluated the relationships between ETS and clinical outcomes by multivariable Cox proportional hazards regression models to adjust for potential confounders, including the clinical and pathologic features. Results: Among the patients, 52% had an ETS of 20% or more, and 48% had an ETS smaller than 20%. The ETS was not significantly associated with any of the clinical or pathologic features examined (all P > 0.09). However, ETS was significantly associated with longer progression-free survival ( P < 0.01). Compared with the ETS-absent group, the multivariable-adjusted hazard ratio (HR) for the ETS-present group was 0.23 (95% confidence interval [Cl], 0.14–0.39; P < 0.01). Similarly, the same trend was observed for overall survival (multivariable-adjusted HR, 0.15; 95% CI, 0.07–0.31; P < 0.01). These prognostic associations of ETS were similarly observed in the ICI+chemotherapy and ICI+ICI groups (all P < 0.01). Conclusions: Early tumor shrinkage was associated with favorable clinical outcomes for ICI-treated patients with unresectable or recurrent ESCC, providing a platform for further investigations of predictive markers and treatment strategies.Keywords
Funding Information
- Japan Society for the Promotion of Science (24K11870 (KK))
- Kumamoto University
This publication has 33 references indexed in Scilit:
- Deep Learning Model for Predicting Immunotherapy Response in Advanced Non−Small Cell Lung CancerJAMA Oncology, 2025
- Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trialCancer Medicine, 2024
- First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 studyEsophagus, 2024
- Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2Esophagus, 2023
- Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807Esophagus, 2022
- First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)Esophagus, 2022
- Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatinEsophagus, 2022
- First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590Esophagus, 2022
- Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)Esophagus, 2020
- Assessment of Intratumoral and Peritumoral Computed Tomography Radiomics for Predicting Pathological Complete Response to Neoadjuvant Chemoradiation in Patients With Esophageal Squamous Cell CarcinomaJAMA Network Open, 2020